CC671 free base · Synonyms: CC-671 · CC 671

CC-671 is a dual TTK protein kinase/CDC2-like kinase inhibitor.

For research use only. Not for human or veterinary use.

Target CDK

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

CC671 structure

CAS No.: 1618658-88-0

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
100 mg	USD 598.00	BP-02506-100mg	In stock	Get quote
250 mg	USD 897.00	BP-02506-250mg	In stock	Get quote
500 mg	USD 1,598.00	BP-02506-500mg	In stock	Get quote
1 g	USD 2,598.00	BP-02506-1g	In stock	Get quote
2 g	Inquire	BP-02506-2g	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

CC-671 is a dual TTK protein kinase/CDC2-like kinase (CLK2) inhibitor with IC50s of 0.005 and 0.006 μM for TTK and CLK2, respectively.

Biological activity

In Vitro CC-671 (compound 23) is a dual TTK protein kinase/CDC2-like kinase (CLK2) inhibitor with IC50s of 0.005 and 0.006 μM for TTK and CLK2, respectively. HCT-116 cell lysates treated with CC-671 at 3 μM for 1 h demonstrates that only four kinases show cellular binding of 75% or more including CLK2, CAMKK2, PIP4K22, and JNK In Vivo CC-671 (compound 23) demonstrates significant tumor growth inhibition (TGI) ((vehicle -treated/vehicle) ×100%) of 71% at both 10 and 20 mg/kg on a every 3 days (q3d) dosing schedule. The body weight loss (BWL) in the CC-671 treated group (20 mg/kg ) is higher than in the 10 mg/kg group (17% vs 5%)

Identifiers

SMILES: CNC(=O)C1=CC=C(NC2=NC(OC3CCCC3)=C3C(NC=C3C3=CC=C4N=C(C)OC4=C3)=N2)C(OC)=C1
InChIKey: CWJLAVRXVFHDSJ-UHFFFAOYSA-N

Specifications

MW (average): 512.5597
Formula: C₂₈H₂₈N₆O₄
CAS No.: 1618658-88-0
Physical state: Solid
Color: Off-white to light green
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20°C 3 years; 4°C 2 years. In solvent -20°C 1 year

Solubility

Soluble in DMSO

Documents

References

[1]. Riggs JR, et al. The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatmentof Triple Negative Breast Cancer Initiated from a Phenotypic Screen. J Med Chem. 2017 Nov 9;60(21):8989-9002.

Same target

Search CDK

Same research area

Search Cancer